BCAAs

The branched-chain amino acids (BCAAs) are a group of three essential amino acids — leucine, isoleucine, and valine — that share a branched aliphatic side chain. Among the nine essential amino acids, only the BCAAs are oxidized primarily outside the liver, making them a unique class in metabolic and nutritional terms.

Biochemistry

BCAA catabolism begins with transamination by branched-chain aminotransferase (BCAT1 in brain, BCAT2 in peripheral tissues including skeletal muscle), yielding the corresponding branched-chain alpha-ketoacid. The irreversible committed step is oxidative decarboxylation by the branched-chain alpha-ketoacid dehydrogenase complex (BCKDH), a mitochondrial enzyme analogous to the pyruvate dehydrogenase complex. Defects in BCKDH cause maple syrup urine disease, a serious inherited metabolic disorder.

BCAAs and muscle protein synthesis

The role of BCAAs in muscle anabolism is mostly attributable to leucine specifically — isoleucine and valine contribute little to mTORC1 activation above basal. Several randomized trials, most notably Jackman et al. (2017) and Wolfe (2017), demonstrate that BCAA supplementation without the full essential amino acid profile elicits only approximately 22% of the MPS response generated by a complete protein bolus providing the same leucine content. This observation is consistent with the "leucine trigger, EAA substrate" model: leucine initiates translation, but sustained protein synthesis requires the full complement of EAAs to build polypeptides.

BCAAs in metabolic disease

A provocative series of metabolomic studies beginning with Newgard et al. (2009) identified elevated plasma BCAA concentrations as one of the strongest metabolic signatures distinguishing obese, insulin-resistant individuals from lean controls. Whether BCAAs are causal contributors to insulin resistance, markers of impaired BCAA catabolism secondary to mitochondrial dysfunction, or byproducts of altered microbial metabolism remains actively debated. The current consensus is that elevated plasma BCAAs reflect a failure of disposal rather than excess intake, and that dietary BCAA restriction in humans has not demonstrated consistent metabolic benefit.

Practical intake considerations

Typical Western diets provide 15-25 g BCAAs per day from whole-protein sources. Supplementation is generally unnecessary when total protein intake is adequate, as whey, casein, egg, beef, and soy proteins all deliver substantial BCAA quantities in the context of complete EAA profiles. The residual use case for isolated BCAA supplementation is narrow: fasted-state training where rapid-onset leucine exposure may be desired, or clinical conditions requiring targeted leucine without nitrogen load.

BCAAs and central fatigue

A separate hypothesis — the "central fatigue hypothesis" of Newsholme and colleagues — proposed that BCAAs compete with tryptophan for blood-brain barrier transport and thereby attenuate serotonin-mediated central fatigue during endurance exercise. Controlled trials have not consistently demonstrated meaningful performance benefit from this mechanism.